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Abstract: Lipoprotein lipase (LPL) is a central enzyme in lipid metabolism. Due to its catalytic activity,
LPL is involved in metabolic pathways exploited by various solid and hematologic malignancies
to provide an extra energy source to the tumor cell. We and others described a link between the
expression of LPL in the tumor cell and a poor clinical outcome of patients suffering Chronic
Lymphocytic Leukemia (CLL). This leukemia is characterized by a slow accumulation of mainly
quiescent clonal CD5 positive B cells that infiltrates secondary lymphoid organs, bone marrow and
peripheral blood. Despite LPL being found to be a reliable molecular marker for CLL prognosis, its
functional role and the molecular mechanisms regulating its expression are still matter of debate.
Herein we address some of these questions reviewing the current state of the art of LPL research in
CLL and providing some insights into where currently unexplored questions may lead to.
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1. Lipoprotein Lipase
Lipoprotein lipase (LPL, EC 3.1.1.34) is a N-glycosylated protein [1] that forms homodimers and
is able to hydrolize triglycerides from chylomicrons [2] and very low-density lipoproteins [3]. The first
evidence of its existence was serendipitously found when studying circulating red blood cell mass in
dogs. In those experiments, it was found that the administration of heparin as an anticoagulant was
able to counteract alimentary lipemia in five minutes or less [4]. LPL plays a central function in lipid
metabolism and has been subject of intense and meticulous studies ever since. General aspects of LPL
biology have already been reviewed elsewhere [5,6].
LPL Synthesis and Trafficking
LPL active dimer consists of two antiparallel subunits [7] whose formation and trafficking rely
on a series of post-translational modifications. Interaction with calcium-dependent chaperones of
the N-glycosylated polypeptide chain has been proven essential to the correct folding of LPL [8].
Furthermore, a lipase chaperon—Lipase-maturation factor 1 (Lmf1)—has been suggested to be required
for dimer assembly and activity, as mutations in LMF1 cause lipase deficiency in mice [9]. A mouse
model overexpressing LMF1 has increased LPL activity [10], and LPL has been co-immunoprecipitated
with Lmf1 and Sortilin-related receptor (SorLA) [11]. It has been shown that LPL intracellular
localization is regulated by SorLA, which directs its trafficking from the trans-Golgi network to
endosomes [11]. LPL internalization by receptor-mediated endocytosis has been studied [12] either
through LDL receptor-related protein [13] or by an LDL-receptor independent pathway [14].
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2. Chronic Lymphocytic Leukemia
Chronic lymphocytic leukemia (CLL) is the most frequent form of leukemia among adult
populations of Caucasian origin [15]. CLL is a malignancy of mature clonal B lymphocytes that
accumulate in the blood, bone marrow and other lymphoid tissues, and is diagnosed upon the
presence of ≥5000 clonal B lymphocytes per microliter of peripheral blood persisting for more than
3 months [16]. This leukemia is characterized by the accumulation of long-lived circulating clonal
leukemic B-cells resulting from a complex balance between cell proliferation and apoptotic death.
Increasing evidence suggests that CLL B-cells in lymph nodes (LN) and bone marrow (BM) that interact
with stromal cells receive proliferative signals and are protected from cell death. These data led to the
view that CLL is a dynamic process composed of cells that also proliferate and die, often at appreciable
levels [17]. This crosstalk with accessory cells in specialized tissue microenvironments favors disease
progression, by promoting malignant B-cell growth and the emergence of new genetic alterations
which will lead to drug resistance [18]. Disease prognosis and the heterogeneous clinical evolution in
CLL are probably related at least in part to these microenvironmental signaling, and although available
treatments often induce remissions, CLL remains an incurable disease [19].
In CLL one third of the patients have an indolent disease with long survival and never require
treatment, another third have an aggressive disease from onset and need to be immediately treated,
and the last third have an indolent disease at onset which may last for years but then invariably
progress to an aggressive disease [20]. It is because of this latter group that the search for strong
prognostic markers in CLL predicting disease evolution has been of capital importance, and a number
of them have been developed, the most reliable and universal still being the mutational status of the
variable region of the heavy chain of immunoglobulin (IgHV) genes [21,22]. Patients carrying somatic
hypermutation in their IgHV genes—mutated CLL (Mut)—display a better prognosis than patients
with unmutated (Um) IgHV genes
3. LPL in Chronic Lymphocytic Leukemia
3.1. LPL As a Prognostic Marker of Disease Progression
Gene expression profiling analyses comparing Um and Mut patients were performed during
the first decade of the century. We and others have performed these studies and described that LPL
is differentially overexpressed in Um patients [23–25]. With these results in mind we selected and
validated two genes, LPL for Um and ADAM29 for Mut CLLs, as candidates to propose a novel
prognostic method. This methodology was tested in a cohort of 127 CLL patients, and correlated to
clinical outcome and IgHV mutational status. Finally, we demonstrated that quantification of LPL and
ADAM29 gene expression ratio is a strong prognostic indicator in CLL, providing better prognostic
assessment than serologic markers in advanced stages of the disease [26]. A body of evidence has
confirmed that the expression of LPL mRNA is associated to bad prognosis, and that it is the most
robust of the molecular markers in CLL [27–33].
The elevated expression of LPL gene in Um CLL B-cells is a very remarkable observation, because
there is no expression of LPL in normal B cells. This specific and ectopic expression constitutes not only
a suitable prognostic marker to study disease evolution, but could also be helpful to understand the
heterogeneous proliferative behavior in CLL. Despite the prognostic value of LPL expression is well
established, the functional role of LPL overexpression in CLL pathogenesis as well as the molecular
mechanisms regulating its expression are still open questions.
Concerning the functional role of LPL in CLL cells, increasing evidence supports the idea
that LPL expression could help the leukemic clone to increase survival and proliferative signaling,
leading to disease progression. We have also shown that microenvironmental signaling can induce
LPL expression and proliferative phenotype in primary CLL B-cells [34,35]. Supporting this idea
Rozovski, Grgurevic, et al. demonstrated that LPL confers CLL a survival advantage, since shRNA
knockdown of LPL increases apoptotic death [36]. Accordingly, it has recently been reported
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that NOTCH1 gene mutations which are associated with disease progression and treatment
refractoriness [37] are directly related to LPL expression in CLL [38].
Concerning the molecular mechanism that regulates LPL expression we previously demonstrated
that abnormal expression of LPL gene in Um CLL patients results from the lack of methylation in the
CpG island involving the whole exon 1 and the first nucleotides of intron 1 of LPL [34]. This epigenetic
mechanism appears to be mainly triggered by proliferative T-cell-dependent signals and, in some
patients, through the cross-linking of the B-cell receptor (BCR). By contrast, signaling through TLR9
or TLR1/2 pathways are unable to induce demethylation of the CpG island, LPL expression and
B-cell proliferation [35]. Rozovski, Grgurevic, et al. have shown that LPL expression can also be
transcriptionally regulated by STAT3 phosphorylation, and nuclear translocation where it can bind
LPL promoter [36]. Additionally, it is necessary to mention that LPL expression can be regulated
post-transcriptionally by miR-29 [39,40]. It has been reported that miR-29 expression is down-regulated
in high-risk Um CLL patients [41–44]. In a more recent study of the microRNAome of a large patient
cohort, down-regulation of miR-29c was the feature better related to IgHV Um profile [45]. In fact,
Santanam et al. have developed a mouse model of early onset indolent CD5+ B-CLL by targeted
overexpression of miR-29 in B-lymphocytes under control of the Eµ enhancer [46]. The authors focused
on the effect on leukemogenesis by the interaction of miR-29 and TCL1 [44,47] and did not evaluate LPL
expression, which would be expected to be low. Deregulation of miR-29 is known to have important
effects in diverse hematological disorders (reviewed in [48]), to respond to cellular signaling processes
such as BCR or CD40 stimulation, and to engage NF-κB activation through TCL1 [47]. Linking these
microenvironmental signaling to the epigenetic changes described by us in Um patients as well as
their correlation with miR-29 and LPL expression could be an interesting issue that is still awaiting to
be studied in CLL progression.
3.2. LPL in CLL B-Cell Metabolism
LPL has been shown to mediate lipolysis and subsequent fatty acid (FA)-mediated fueling
of cell proliferation in several solid tumors [49], and it has recently been shown that low-density
lipoproteins may enhance proliferative responses of CLL cells to inflammatory signals [50].
PPARα protein levels in CLL B-cells have been shown to correlate with leukocytosis and clinical
Rai stages, which suggests a metabolic switch to oxidation of fatty acids via PPARα [51] and
PPARδ [50]. These findings are supported by the observation that CLL B-cells have lipid vacuoles in
their cytoplasm, and that incubation with free fatty-acids (FFAs) increased their metabolic rate in terms
of oxygen consumption [36]. Furthermore, the incidence of hyperlipidemia has been found to be higher
in CLL patients, and treatment of hyperlipidemia with statins benefited them in terms of a delayed time
to first treatment [52]. The same group expanded their initial study to a cohort of >2000 CLL patients in
a retrospective analysis and found that both lipid-lowering drugs, as well as statin treatment prolonged
overall survival by 3.7 years [53]. These findings suggest that a second mechanism mediated by LDL
may be converging in STAT3 phosphorylation and generating an activated state in CLL B-cells [50].
Transcriptional profiling identified a metabolic shift into a muscle or adipose tissue-like strategy
with lipid oxidation in poor prognosis Um IgHV and LPL expressing B CLL cells [54]. How this
metabolic reprogramming ends up in a worse outcome for patients is only beginning to be understood.
Long chain fatty acids, free cholesterol and vitamin E- increase STAT3 phosphorylation directed
either by IL-10, IFNα or phorbol esters in CLL cells [50]. STAT3 phosphorylation in turn drives LPL
expression directly, by binding to a GAS-like element 280 bp upstream of the LPL transcription start
site and activating its transcription [36]. LPL expression favors FA oxidation, and this seems to result
in higher cell survival as LPL knockdown or chemical inhibition reduced CLL cell viability [36,55],
which might be explained in part by a transcriptional response [32]. Accordingly, microenvironmental
induction of LPL expression stimulates CLL cell proliferation [35]. These findings indicate that LPL
expression can be regulated by the microenvironment, either by autocrine or paracrine signaling and
that it reflects a metabolic switch in CLL B-cells which confers an adaptive advantage. A positive
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feedback loop may maintain LPL expression and worsen the scenario for Um patients. In CLL, STAT3 is
constitutively activated which also activates LPL transcription [36]. LPL breaks down very low-density
lipoproteins (VLDL) and chylomicrons and liberates FFAs, generating a proinflammatory state which
in turn activates STAT3 [51] and further activation of LPL transcription. This would further increase
the levels of FFAs, thus exacerbating CLL cells responsiveness to cytokine signaling. More general
aspects of metabolic pathways in CLL have been nicely reviewed recently [56].
3.3. Non-Metabolic Roles of LPL in CLL
Many studies have reported an increased expression of LPL in poor prognosis CLL, and several
metabolic pathways could be involved in cancer progression as discussed above. However, attempts
to determine metabolic activity of LPL directly have failed to correlate higher expression to higher
metabolic activity. A seminal study with 33 CLL patients reported lower catalytic activity in Um
patients than in their Mut counterpart [30]. Another report analyzing data from 42 patients did not
find differences between CLL groups and reported that LPL activity was comparable to that of healthy
individuals [32].
LPL can mediate lipoprotein uptake by cells [57], chylomicron attachment to cell surface
through LDL-related receptor [58], and lipoprotein margination in small blood vessels, by binding
on the one hand to the extracellular surface of endothelium via GPIHBP1, and on the other to
triglyceride-rich lipoproteins [59]. Besides its canonical role in lipid metabolism, an interesting—yet
quite unexplored—non-metabolic function of LPL has been known for 20 years. LPL can act as a
bridging molecule between cells, as in the adhesion of monocytes to endothelial cells mediated by
heparan sulfate proteoglycans (HSPGs) and LPL [60], whose interaction has recently been shown to
be dynamic [61]. Provided that CLL cells display HSPGs on their surface [62] and that LPL forms
homodimers, it could occur that a bridging between leukemic B-cells and other cells expressing surface
HSPGs or GPIHBP1 such as endothelial cells would be mediated by LPL. Although several groups
have already speculated about it, a cell–cell bridging role for LPL in CLL pathogenesis still has to be
demonstrated [30,35,63]. If such a bridging actually occurred, LPL would be pivoting between surface
HSPGs on the B-CLL cell side, and either HSPGs or GPIHBP1 on their counterpart.
Rombout et al. have found that two SNPs commonly found in LPL, rs328 (premature stop codon)
and rs13702 were significantly associated with CLL outcome [63]. Although both SNPs are well-known
gain-of-function mutations [64,65], the authors of the aforementioned study reported not to have been
able to detect significant differences in LPL mRNA, protein levels, or enzymatic activity in patients
carrying the SNPs [63]. How these mutations affect clinical outcome in CLL is still unclear, but whether
these SNPs might have a role—if any—in LPL non-metabolic functions has not been explored yet.
Furthermore, at least nine isoelectric point isoforms of LPL have been described in human blood
of healthy individuals [66], thus opening a new dimension of studies to come for LPL in CLL and
other pathologies.
4. Concluding Remarks
LPL is a protein located on the luminal side of the blood vessel wall, where it is anchored
to heparan sulfate proteoglycans and contains binding sites for both heparan sulfate chains and
apoproteins [67]. LPL is overexpressed in B-cells of unmutated IgHV CLL patients, and its expression
can be used to predict their clinical outcome [23–33]. Accordingly, LPL could have a bridging function
in the formation of a trimolecular complex including a lipoprotein particle, LPL and heparan sulfate
proteoglycans from different cells [67]. The fact that CLL B-cells display heparan sulfate proteoglycans
on their surface [62], invites to speculate about whether LPL localization on the cellular membrane
could affect the biological behavior of CLL cells, by favoring cell spreading, migration and intracellular
signaling following activation of the tumoral clone by an activated microenvironment. If it is the case,
LPL might also act as a crosstalk factor facilitating specific interactions with accessory cells in tissue
microenvironments. LPL might then be added to the list of proteins implicated in the activation
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of CLL proliferative pool together with integrins such as CD49d, metalloproteinases (MMP-9),
antiapoptotic molecules (BCL2) as well as chemokines (CCL3, CCL4, CXCL12) [68,69]. Thus, LPL could
be contributing to leukemic progression either per se through metabolic reprogramming, or through the
synergistic contribution to an activating microenvironment in which the leukemic clone is continuously
nourished (Figure 1).
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would contribute to microenvironmental crosstalk. LPL would act as a bridging molecule between cells 
able to bind LPL either by heparan sulfate proteoglycans or GPIHBP1, thus facilitating modulatory 
interactions, exemplified here by a T-cell dependent activation through CD40/CD40L interaction. 
The role that abnormal LPL expression could have in disease evolution, has also been addressed 
by previous work from Pallasch et al., demonstrating that lipase associated genes and triglyceride-
specific lipase activity were significantly increased when comparing CLL B-cells to normal CD5+ B-
cells [55]. The same authors reported that incubation of CLL tumoral cells with the lipase inhibitor 
orlistat resulted in increased apoptosis, which, could suggest that lipid metabolism and lipase activity 
could be functionally relevant in aggressive CLL [55]. Phenotypic analyses have shown that CLL B-
cells expressing LPL are also enriched in FA degradation genes [54]. Recently, LPL has been shown 
to mediate lipolysis and subsequent FA-mediated fueling of cell proliferation in several solid tumors 
[49], and it has recently been shown that low-density lipoproteins may enhance proliferative 
responses of CLL cells to inflammatory signals [50].  
A big amount of information is known nowadays about LPL some of which relates to CLL. Still, 
our understanding whether LPL overexpression in poor outcome CLL is a cause or consequence is 
poor. Many questions are still open and more answers will certainly come in next years. 
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Figure 1. Hypothetical model of LPL function in CLL B-cells in secondary lymphoid organs (SLO, left)
and peripheral blood (PB, right). HSPG-attached LPL molecules at the surface of B-CLL cells can bind
very low-density lipoproteins and chylomicrons thus contributing to oxidative metabolism and fatty-acid
signaling. LPL has been proposed to play a similar role in the intracellular compartment by releasing FFAs
from cytosolic lipid droplets [36,56]. A non-canonical role for LPL in CLL B-cell surface would contribute
to microenvironmental crosstalk. LPL would act as a bridging molecule between cells able to bind LPL
either by heparan sulfate proteoglycans or GPIHBP1, thus facilitating modulatory interactions, exemplified
here by a T-cell dependent activation through CD40/CD40L interaction.
The role that abnormal LPL expression could have in disease evolution, has also been addressed by
previous work from Pallasch et al., demonstrating that lipase associated genes and triglyceride-specific
lipase activity were significantly increased when comparing CLL B-cells to normal CD5+ B-cells [55].
The same authors reported that incubation of CLL tumoral cells with the lipase inhibitor orlistat
resulted in increased apoptosis, which, could suggest that lipid metabolism and lipase activity could
be functionally relevant in aggressive CLL [55]. Phenotypic analyses have shown that CLL B-cells
expressing LPL are also enriched in FA degradation genes [54]. Recently, LPL has been shown to
mediate lipolysis and subsequent FA-mediated fueling of cell proliferation in several solid tumors [49],
and it has recently been shown that low-density lipoproteins may enhance proliferative responses of
CLL cells to inflammatory signals [50].
A big amount of information is known nowadays about LPL some of which relates to CLL.
Still, our understanding whether LPL overexpression in poor outcome CLL is a cause or consequence
is poor. Many questions are still open and more answers will certainly come in next years.
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